First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).
about
First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
First line raltegravir/emtrici ...... rative trial (ANRS 159 HIV-2).
@en
First line raltegravir/emtrici ...... phase 2 non-comparative trial
@nl
type
label
First line raltegravir/emtrici ...... rative trial (ANRS 159 HIV-2).
@en
First line raltegravir/emtrici ...... phase 2 non-comparative trial
@nl
prefLabel
First line raltegravir/emtrici ...... rative trial (ANRS 159 HIV-2).
@en
First line raltegravir/emtrici ...... phase 2 non-comparative trial
@nl
P2093
P2860
P50
P356
P1476
First line raltegravir/emtrici ...... rative trial (ANRS 159 HIV-2).
@en
P2093
ANRS 159 HIV-2 trial Study Group
Amel Besseghir
Diane Ponscarme
Emmanuel Mortier
Fideline Collin
Francoise Brun-Vezinet
Laurent Blum
Pierre Sellier
Roland Tubiana
Sebastien Gallien
P2860
P356
10.1093/CID/CIY245
P407
P577
2018-03-24T00:00:00Z